4-(5-formylpyridin-2-yloxy)benzonitrile | 328547-41-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(5-formylpyridin-2-yloxy)benzonitrile
• 英文别名: 4-[(5-Formyl-2-pyridinyl)oxy]benzenecarbonitrile；4-(5-formylpyridin-2-yl)oxybenzonitrile
• CAS: 328547-41-7
• 化学式: C₁₃H₈N₂O₂
• 分子量: 224.219
• InChiKey: AQJFLLNUQBDTIN-UHFFFAOYSA-N

物化性质

• 熔点：
  133-135,5°C
• 沸点：
  418.4±40.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(5-formylpyridin-2-yloxy)benzonitrile 、 三甲基硅烷化重氮甲烷 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醚 、 正庚烷 、 邻二乙苯 为溶剂， 反应 4.5h， 以49%的产率得到4-(5-ethynylpyridin-2-yloxy)benzonitrile
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Inhibitors of Botulinum Neurotoxin Metalloprotease

  摘要：

  Based on the lead therapeutic agent NSC 240898, a new series of heterocyclic inhibitors of the BoNT serotype A metalloprotease has been generated. Highlights of the synthetic sequences include Sonogashira couplings of polysubstituted building blocks and gold-catalyzed indole formations. Preliminary structure-activity relationship studies afford detailed insights into the steric and electrostatic properties of the pharmacophore of this molecular scaffold.

  DOI：

  10.3987/com-08-s(d)8
• 作为产物：
  描述：

  4-羟基苯甲腈 、 2-溴-5-醛基吡啶 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以77%的产率得到4-(5-formylpyridin-2-yloxy)benzonitrile
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Inhibitors of Botulinum Neurotoxin Metalloprotease

  摘要：

  Based on the lead therapeutic agent NSC 240898, a new series of heterocyclic inhibitors of the BoNT serotype A metalloprotease has been generated. Highlights of the synthetic sequences include Sonogashira couplings of polysubstituted building blocks and gold-catalyzed indole formations. Preliminary structure-activity relationship studies afford detailed insights into the steric and electrostatic properties of the pharmacophore of this molecular scaffold.

  DOI：

  10.3987/com-08-s(d)8

文献信息

• TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1208104A2

  公开（公告）日：2002-05-29
• US6548494B1
  申请人：——

  公开号：US6548494B1

  公开（公告）日：2003-04-15
• [EN] TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES<br/>[FR] INHIBITEURS TRICYCLIQUES DE POLY(ADP-RIBOSE) POLYMERASES
  申请人：AGOURON PHARMA

  公开号：WO2001016136A2

  公开（公告）日：2001-03-08

  Compounds of the formula (I) are poly(ADP-ribosyl)transferase inhibitors. Such compounds are useful as therapeutics in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease.
• Synthesis and Biological Evaluation of Inhibitors of Botulinum Neurotoxin Metalloprotease
  作者：Peter Wipf、Chenbo Wang、Julia Widom、Filip Petronijevic、James C. Burnett、Jonathan E. Nuss、Sina Bavari、Rick Gussio

  DOI：10.3987/com-08-s(d)8

  日期：——

  Based on the lead therapeutic agent NSC 240898, a new series of heterocyclic inhibitors of the BoNT serotype A metalloprotease has been generated. Highlights of the synthetic sequences include Sonogashira couplings of polysubstituted building blocks and gold-catalyzed indole formations. Preliminary structure-activity relationship studies afford detailed insights into the steric and electrostatic properties of the pharmacophore of this molecular scaffold.